Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by porksnifferon Mar 26, 2020 6:55pm
126 Views
Post# 30851262

RE:RE:RE:obviously ...

RE:RE:RE:obviously ...
wagyusteak wrote:
porksniffer wrote:
MUGMODs wrote: When the GUD share price goes on a ride upwards, only to finish the day coming back to earth, I believe that is characteristic of buy-backs.

One main buyer and when they stop buying, demand dries up and the share price returns.

Not manipulation ... internal buying (IMO).


I see you didn't take your meds today lol. Every single share purchased by this management has resulted in losses of up to 25% or millions of dollars to shareholders.

Still waiting for years of these alleged buying of yours to be posted here. What you should be questioning is why this turd is in no rush to release earnings. Been almost 5 months, FIVE months no report.



Correct me if I'm wrong but it looks like they've filed it. Just dont know why we don't have the public filings yet.

https://www.ic.gc.ca/app/scr/cc/CorporationsCanada/fdrlCrpDtls.html?corpId=9076417&V_TOKEN=1585253553609&crpNm=knight%20therapeutics&crpNmbr=&bsNmbr=



They have filed nothing. Last year earnings were March 14th this, here we are March 26th..nothing. Not even a press release of what date to expect. Unbelievable.

The 90 day limit is here last legal day for filing is Tuesday. What kind of company does this? Not even the most speculative penny stocks do this.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities